Preterm Birth and PROM Testing Market Surpass $1.31 Billion By 2026 | CAGR 1.74%

Author: Acumen Research and Consulting

The global market size of preterm birth and PROM testing is expected to reach 1.31 billion by the end of year 2026. The market is estimated to grow at a CAGR of 1.74% over the forecast period.

Premature rupture of membranes (PROM) causes roughly 4.5 Million preterm births every year, around the world. Comprehensively, premature birth is among the most incessant reasons for death among neonates within the first month of their life. The endorsement of preterm birth and PROM testing demonstrative units has presented an exceptionally effectual yet cost-effective choice for testing premature rupture of membranes in symptomatic patients. These tests are progressively supplanting conventional standard-of-care tests (Fern and Nitrazine) propelled by their usability and high affectability.

Download Report Sample Pages For Better Understanding@ 

Rising adoption of biomarker test units is projected to drive the market in the next few years. High precision of these tests results in the early determination of preterm work, diminishes the opportunity of neonatal diseases and fatality, decreases the number of high-hazard patients, and limits excessive treatment costs. Expanding interest for improved medicinal services, high treatment expenses, and rising worldwide populace are projected to additionally push the point-of-care testing market, which in turns, fuelling the provision of preterm birth and PROM testing.

Rise in awareness regarding specialty medications is one of the key factors that are driving the diagnostics laboratories segment over the forecast period. Also, a rise in demand for preterm symptomatic administrations and an increase in the number of indicative techniques, for instance, ultrasound and pelvic examinations for pregnant ladies are projected to drive the segment. The others section is expected to register a significant rate of growth attributable to the change of treatment toward nursing homes and concentrated clinics.

The global preterm birth and PROM testing market is divided into test type, end-user, and region. On the basis of test type segment, the worldwide preterm birth and PROM testing market is divided into preterm birth tests and PROM tests. Whereas, preterm birth tests segment includes pelvic exam, ultrasound, uterine monitoring, and biomarkers, and prom test includes nitrazine test, ferning test, pooling, ultrasound, fetal fibronectin test, biomarker tests, and others. On the basis of application, the worldwide preterm birth and PROM testing market is segmented into hospitals, diagnostic laboratories, and others. Based on the region, the worldwide preterm birth and PROM testing market is divided into North America, Latin America, Europe, Middle East and Africa, and the Asia Pacific.

Consistently, around 5 mn children around the globe are conceived before the 37th week of pregnancy and the number is required to increment further. Around 1 mn kids kick the bucket every year because of difficulties brought about by preterm births. Premature Rupture of Membranes (PROM) causes about 4.5 million preterm births every year, around the world. Preterm birth is among the most common reasons for death among neonates within the primary month of their life.


In addition, increased average age group of pregnant ladies (>35 years old) has prompted an expansion in the danger of health conditions, for instance, hypertension and diminished bloodstream to the placenta. These issues hazard the strength of both the mother and the unborn and often result in preterm births or neonatal passings. Despite the fact that conventional methods, for instance, Nitrazine and Ferning test make it conceivable to get negative prescient esteem (NPV), they have very poor positive prescient qualities for unconstrained convey. The endorsement of PartaSure (Parsagen Diagnostics, Inc., and Qiagen) in April 2018 and other improved demonstrative test units have presented profoundly adequate yet practical choices for PROM testing in symptomatic victims.

Asia Pacific market is estimated to witness the fastest CAGR of 2.8% over the estimated time frame. Key factors due to the development of the district incorporate high prevalence of premature births, increase in awareness with respect to maternal health, an increment in medicinal services spending, and steady government activities in creating economies. North America market is capturing a dominated share of the global market in 2018. The rising rate of premature births, poor way of life decisions, and expanding maternal age are some factors that are driving the market in this locale.

Major companies contributing the global preterm birth and PROM testing market are Qiagen, Hologic, Cooper Surgical, Abbott Laboratories, Medixbiochemica, Sera Prognostics, Biosynex, and IQ Products.


The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report - 

Would like to place an order or any question, please feel free to contact at